$LBIO: NEW YORK, NY--(Marketwired - June 03, 2016)
Post# of 22755
Posted On: 06/03/2016 11:51:30 AM
$LBIO: NEW YORK, NY--(Marketwired - June 03, 2016) - Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs), announced today that Lion management will present a company overview at the upcoming Jefferies 2016 Healthcare Conference on Tuesday, June 7, 2016 at 2:30pm E.T in New York, NY .
A live webcast of the presentation will be available by visiting the Investors section of Lion Biotechnologies' website at http://ir.lbio.com/. A replay of the webcast will be archived on Lion Biotechnologies' website for 30 days following the presentation.
About Lion Biotechnologies Lion Biotechnologies, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) for the treatment of patients with refractory metastatic melanoma, and is based on a clinical Cooperative Research and Development Agreement with the National Cancer Institute. TIL therapy is also being evaluated in physician-sponsored clinical trials at MD Anderson Cancer Center and Moffitt Cancer Center. For more information, please visit http://www.lionbio.com.
A live webcast of the presentation will be available by visiting the Investors section of Lion Biotechnologies' website at http://ir.lbio.com/. A replay of the webcast will be archived on Lion Biotechnologies' website for 30 days following the presentation.
About Lion Biotechnologies Lion Biotechnologies, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) for the treatment of patients with refractory metastatic melanoma, and is based on a clinical Cooperative Research and Development Agreement with the National Cancer Institute. TIL therapy is also being evaluated in physician-sponsored clinical trials at MD Anderson Cancer Center and Moffitt Cancer Center. For more information, please visit http://www.lionbio.com.
(2)
(0)Scroll down for more posts ▼